Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats
- PMID: 16636194
- DOI: 10.1161/01.HYP.0000221605.94532.71
Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats
Abstract
We have shown recently that fasudil, a Rho-kinase inhibitor, has renoprotective effects in salt-sensitive hypertensive rats. We hypothesized that activation of Rho-kinase is involved in the pathogenesis of glomerulosclerosis in malignant hypertensive rats. To test this hypothesis, we studied the following 4 groups: control Wistar-Kyoto rats, untreated deoxycorticosterone-acetate salt spontaneously hypertensive rats (DOCA-SHR), low-dose fasudil-treated DOCA-SHR, and high-dose fasudil-treated DOCA-SHR. After 3 weeks of treatment, the effects of fasudil were examined. DOCA-SHR was characterized by increased blood pressure (BP); increased kidney weight; decreased renal function; increased proteinuria; abnormal histological findings; increased monocyte/macrophage infiltration; increased urinary 8-isoprostran levels; increased gene expression of collagen I, collagen III, transforming growth factor-beta, and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits (p40phox, p47phox, and p67phox); and decreased gene expression of endothelial NO synthase (eNOS) in the renal cortex as compared with Wistar-Kyoto rats. Long-term high-dose fasudil treatment significantly improved renal function and histological findings without changing BP, as compared with untreated DOCA-SHR. Interestingly, long-term fasudil treatment significantly decreased monocyte/macrophage infiltration and urinary 8-isoprostran excretion, in association with decreased mRNA levels of transforming growth factor-beta, collagen I, collagen III, and NADPH oxidase subunits (p40phox, p47phox, and p67phox), and increased mRNA levels of eNOS in the renal cortex. Long-term low-dose fasudil treatment tended to improve these variables slightly but did not affect most of them significantly. Our results suggest that long-term fasudil treatment provides renoprotective effects independent of BP-lowering activity. These renoprotective effects are associated with inhibition of extracellular matrix gene expression, monocyte/macrophage infiltration, oxidative stress, and upregulation of eNOS gene expression.
Similar articles
-
Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats.J Hypertens. 2007 May;25(5):1053-63. doi: 10.1097/HJH.0b013e3280825440. J Hypertens. 2007. PMID: 17414670
-
Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats.J Hypertens. 2008 Sep;26(9):1837-48. doi: 10.1097/HJH.0b013e328305086c. J Hypertens. 2008. PMID: 18698220
-
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.Kidney Int. 2003 Dec;64(6):2009-19. doi: 10.1046/j.1523-1755.2003.00300.x. Kidney Int. 2003. PMID: 14633123
-
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.J Pharmacol Sci. 2006 Jan;100(1):22-8. doi: 10.1254/jphs.fmj05003x5. Epub 2006 Jan 6. J Pharmacol Sci. 2006. PMID: 16397372 Review.
-
[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].Nihon Yakurigaku Zasshi. 2006 Sep;128(3):153-9, 152. doi: 10.1254/fpj.128.153. Nihon Yakurigaku Zasshi. 2006. PMID: 16971778 Review. Japanese. No abstract available.
Cited by
-
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.Int J Obes (Lond). 2012 Aug;36(8):1062-71. doi: 10.1038/ijo.2011.232. Epub 2011 Dec 20. Int J Obes (Lond). 2012. PMID: 22184057 Free PMC article.
-
Tanshinone II a protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway.Chin J Integr Med. 2014 Mar;20(3):216-23. doi: 10.1007/s11655-013-1380-3. Epub 2014 Mar 4. Chin J Integr Med. 2014. PMID: 24615214
-
End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.World J Cardiol. 2015 Jan 26;7(1):31-42. doi: 10.4330/wjc.v7.i1.31. World J Cardiol. 2015. PMID: 25632317 Free PMC article.
-
Role of a RhoA/ROCK-Dependent Pathway on Renal Connexin43 Regulation in the Angiotensin II-Induced Renal Damage.Int J Mol Sci. 2019 Sep 7;20(18):4408. doi: 10.3390/ijms20184408. Int J Mol Sci. 2019. PMID: 31500276 Free PMC article.
-
Rho kinase inhibition in diabetic kidney disease.Br J Clin Pharmacol. 2013 Oct;76(4):551-9. doi: 10.1111/bcp.12196. Br J Clin Pharmacol. 2013. PMID: 23802580 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources